Currently, children cannot be reliably screened until they can read. By then, the window for effective intervention is closing fast. CogGen’s saliva sample screening test is the first of it’s kind and can be administered as early as infancy.
Today, dyslexia is most commonly diagnosed using a reading assessment administered by a specialist only after a child first demonstrates an extended period of academic decline and social struggle. Current testing is prohibitively expensive, time consuming, and not scalable. Age and reading level requirements for assessments means optimal intervention time is lost even before the condition is identifiable. “Early recognition that children may be at risk for LD can prevent years of struggle and self-doubt.” – Sheldon Horowitz, Ed.D., Director of LD Resources, National Center for Learning Disabilities
CogGen’s screening uses a simple saliva sample collection kit with results expected to be available within 7-10 business days from a CLIA-certified lab.
CogGen’s pre-symptomatic screening test methodology risk stratifies individuals for the three critical LD impairments. Those stratified as “highest-risk” can be monitored and prioritized for direct professional confirmation and “in-time” intervention.
LDs arise from genetic mutations.
The key advantages of our Genetic approach:
Genetic testing is NOT reading based. The screener can be run at any age to identify risk prior to symptoms.
Patent-pending proprietary markers protect key areas of our science and competitive advantages for our company.
This technology uses PCR which allows us to use saliva samples for our DNA-sequencing platform. The non-invasive nature of our technology will allow is especially important for use in young children.
Multiple studies have shown high clinical utility of key markers in our proprietary screening tool. We can identify at-risk children at a very early age, allowing for the earliest possible intervention.